New pill shows promise against tough prostate cancer
NCT ID NCT05067140
First seen May 08, 2026 · Last updated May 08, 2026
Summary
This study tests an experimental drug called ARV-766, taken as a pill, in men whose prostate cancer has spread to other parts of the body. The drug is given alone or with another medication (abiraterone) to see if it is safe and can shrink tumors or lower PSA levels. About 152 men with advanced prostate cancer will participate in this early-phase trial.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER METASTATIC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Clinical Trial Site
Duarte, California, 91010, United States
-
Clinical Trial Site
Fresno, California, 93720, United States
-
Clinical Trial Site
La Jolla, California, 92037, United States
-
Clinical Trial Site
Orange, California, 92868, United States
-
Clinical Trial Site
Santa Monica, California, 90404, United States
-
Clinical Trial Site
New Haven, Connecticut, 06510, United States
-
Clinical Trial Site
Washington D.C., District of Columbia, 20007, United States
-
Clinical Trial Site
Lake Mary, Florida, 32746, United States
-
Clinical Trial Site
Chicago, Illinois, 60611, United States
-
Clinical Trial Site
New Orleans, Louisiana, 70112, United States
-
Clinical Trial Site
Baltimore, Maryland, 21204, United States
-
Clinical Trial Site
Boston, Massachusetts, 02114, United States
-
Clinical Trial Site
Detroit, Michigan, 48201, United States
-
Clinical Trial Site
Buffalo, New York, 14203, United States
-
Clinical Trial Site
New York, New York, 10065, United States
-
Clinical Trial Site
Philadelphia, Pennsylvania, 19144, United States
-
Clinical Trial Site
Pittsburgh, Pennsylvania, 15232, United States
-
Clinical Trial Site
Myrtle Beach, South Carolina, 29572, United States
-
Clinical Trial Site
Nashville, Tennessee, 37203, United States
-
Clinical Trial Site
San Antonio, Texas, 78229, United States
-
Clinical Trial Site
Charlottesville, Virginia, 22908, United States
-
Clinical Trial Site
Fairfax, Virginia, 22031, United States
-
Clinical Trial Site
Madison, Wisconsin, 53705, United States
Conditions
Explore the condition pages connected to this study.